Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Kevin C. Soares

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0406-017X; OpenAlex author ID A5058857144, A5121159618, A5129659278. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 4, last author 1)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
172
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers, 1 trial · 2025: 12 papers, 1 grant · 2026: 5 papers, 1 trial

Papers 32

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  3. Pancreatic Cancer: Translating Tumor Biology into Actionability. Co-author DOI 10.1158/2159-8290.cd-25-2014↗
  4. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  5. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  6. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.70088↗
  7. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Co-author DOI 10.1002/ctm2.70416↗
  8. Advances in Vaccine-Based Therapies for Pancreatic Cancer. First author DOI 10.1007/s12029-025-01165-4↗
  9. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08426-5↗
  10. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  11. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  12. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  13. Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First. First author DOI 10.1200/edbk-25-473204↗
  14. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  15. ASO Author Reflections: Targeted Treatment for a Rare Subset of Pancreatic Cancer? First author DOI 10.1245/s10434-024-16451-x↗
  16. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  17. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.3389/fonc.2025.1584167↗
  18. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  19. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Co-author DOI 10.1245/s10434-023-14375-6↗
  20. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  21. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  22. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  23. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  24. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  25. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  26. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  27. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  28. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  29. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  30. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  31. Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. First author DOI 10.21037/hbsn.2016.08.06↗
  32. Vaccines for pancreatic cancer. Co-author DOI 10.1097/ppo.0b013e3182756903↗

Trials 2

  1. A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer Principal investigator NCT07671339↗
  2. Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal … Principal investigator NCT06305728↗

Grants 1

  1. Clinical Accelerator Initiative grant: Kevin Soares AWARD lustgarten:2025-kevin-soares-clinical-accelerator-initiative-grant-ke

Closest collaborators

The 25 strongest of 172 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alice Chia-Chi Wei · 15 shared papers, 2021–2026 · strength 2.60
  2. Vinod P. Balachandran · 15 shared papers, 2021–2026 · strength 2.53
  3. Michael Ian D'Angelica · 14 shared papers, 2021–2026 · strength 2.42
  4. William R. Jarnagin · 14 shared papers, 2021–2026 · strength 2.42
  5. Jeffrey A. Drebin · 13 shared papers, 2021–2026 · strength 2.23
  6. Eileen Mary O'Reilly · 12 shared papers, 2021–2026 · strength 2.14
  7. T. Peter Kingham · 10 shared papers, 2021–2025 · strength 1.58
  8. Wungki Park · 8 shared papers, 2021–2026 · strength 1.53
  9. Anna M. Varghese · 9 shared papers, 2021–2026 · strength 1.44
  10. Alex B. Blair · 5 shared papers, 2017–2025 · strength 1.09
  11. Fiyinfolu O. Balogun · 5 shared papers, 2025–2026 · strength 1.06
  12. Marsha Reyngold · 5 shared papers, 2021–2026 · strength 1.04
  13. Kenneth H. Yu · 6 shared papers, 2021–2026 · strength 0.99
  14. Christine A. Iacobuzio–Donahue · 5 shared papers, 2022–2026 · strength 0.92
  15. Christopher H. Crane · 5 shared papers, 2021–2026 · strength 0.87
  16. T. Peter Kingham · 4 shared papers, 2025–2026 · strength 0.84
  17. Benjamin D. Greenbaum · 5 shared papers, 2022–2026 · strength 0.79
  18. Jin Peng He · 6 shared papers, 2017–2025 · strength 0.69
  19. Caitlin A. McIntyre · 4 shared papers, 2022–2026 · strength 0.65
  20. Peter J. Allen · 4 shared papers, 2022–2025 · strength 0.61
  21. Robert J. Torphy · 2 shared papers, 2025 · strength 0.57
  22. Marinela Capanu · 3 shared papers, 2025–2026 · strength 0.54
  23. Matthew T. McMillan · 1 shared paper, 2025 · strength 0.54
  24. Olca Baştürk · 3 shared papers, 2025–2026 · strength 0.52
  25. Mara H. Sherman · 2 shared papers, 2026 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.